{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:23Z","timestamp":1792093763160,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373362"],"award-info":[{"award-number":["82373362"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cellsig.2026.112947","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:24:06Z","timestamp":1791933846000},"page":"112947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the HIF-1\u03b1\u2013BSG metabolic circuit reverses enzalutamide resistance in prostate cancer"],"prefix":"10.1016","volume":"149","author":[{"given":"Xiuchen","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10305","key":"10.1016\/j.cellsig.2026.112947_bb0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cellsig.2026.112947_bb0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"13","key":"10.1016\/j.cellsig.2026.112947_bb0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112947_bb0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112947_bb0025","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14737140.2024.2405103","article-title":"Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment","volume":"24","author":"Miller","year":"2024","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112947_bb0030","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112947_bb0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112947_bb0040","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.cellsig.2026.112947_bb0045","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112947_bb0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13062-024-00550-6","article-title":"The impact of androgen-induced translation in modulating androgen receptor activity","volume":"19","author":"Israel","year":"2024","journal-title":"Biol. Direct"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112947_bb0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jb\/mvv127","article-title":"Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners","volume":"159","author":"Muramatsu","year":"2016","journal-title":"J. Biochem."},{"issue":"15","key":"10.1016\/j.cellsig.2026.112947_bb0065","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","article-title":"CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression","volume":"19","author":"Kirk","year":"2000","journal-title":"EMBO J."},{"issue":"40","key":"10.1016\/j.cellsig.2026.112947_bb0070","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.1073\/pnas.1106123108","article-title":"CD147 subunit of lactate\/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors","volume":"108","author":"Floch","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-14-2260","article-title":"Genetic disruption of lactate\/H+ symporters (MCTs) and their subunit CD147\/BASIGIN sensitizes glycolytic tumor cells to phenformin","volume":"75","author":"Marchiq","year":"2015","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112947_bb0080","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/carcin\/bgs196","article-title":"Hypoxia upregulates CD147 through a combined effect of HIF-1\u03b1 and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors","volume":"33","author":"Ke","year":"2012","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.cellsig.2026.112947_bb0085","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ijc.25982","article-title":"Expression of CD147 is associated with prostate cancer progression","volume":"130","author":"Zhong","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellsig.2026.112947_bb0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1471-2407-11-312","article-title":"Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer","volume":"11","author":"P\u00e9rtega-Gomes","year":"2011","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112947_bb0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/sj.bjc.6605839","article-title":"Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression","volume":"103","author":"Hao","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.cellsig.2026.112947_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040716","article-title":"In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 OR CD147","volume":"7","author":"Hao","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112947_bb0105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.4547","article-title":"A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy","volume":"236","author":"Pertega-Gomes","year":"2015","journal-title":"J. Pathol."},{"issue":"13","key":"10.1016\/j.cellsig.2026.112947_bb0110","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/emboj.2011.158","article-title":"The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis","volume":"30","author":"Massie","year":"2011","journal-title":"EMBO J."},{"issue":"45","key":"10.1016\/j.cellsig.2026.112947_bb0115","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/onc.2013.463","article-title":"Androgens regulate prostate cancer cell growth via an AMPK-PGC-1\u03b1-mediated metabolic switch","volume":"33","author":"Tennakoon","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-026-02602-z","article-title":"KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate\/hnRNPA1 lactylation\/AR-v7 axis","volume":"25","author":"Sun","year":"2026","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112947_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112947_bb0130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","article-title":"Hypoxia-inducible factors: master regulators of cancer progression","volume":"2","author":"Schito","year":"2016","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112947_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12918","article-title":"PRKAR2B-HIF-1\u03b1 loop promotes aerobic glycolysis and tumour growth in prostate cancer","volume":"53","author":"Xia","year":"2020","journal-title":"Cell Prolif."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112947_bb0140","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"10.1016\/j.cellsig.2026.112947_bb0150","doi-asserted-by":"crossref","first-page":"26259","DOI":"10.18632\/oncotarget.8456","article-title":"Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer","volume":"7","author":"Kregel","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112947_bb0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","article-title":"Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression","volume":"8","author":"Varambally","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112947_bb0160","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/srep16018","article-title":"Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy","volume":"5","author":"Mortensen","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0165","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","article-title":"Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer","volume":"15","author":"Kiviaho","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112947_bb0170","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.cellsig.2026.112947_bb0175","article-title":"hdWGCNA identifies co-expression networks in high-dimensional transcriptomics data","volume":"3","author":"Morabito","year":"2023","journal-title":"Cell Rep Methods"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/bioadv\/vbac016","article-title":"Decoupler: ensemble of computational methods to infer biological activities from omics data","volume":"2","author":"Badia-I-Mompel","year":"2022","journal-title":"Bioinform Adv"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112947_bb0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","article-title":"Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112947_bb0190","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nmeth.4463","article-title":"SCENIC: single-cell regulatory network inference and clustering","volume":"14","author":"Aibar","year":"2017","journal-title":"Nat. Methods"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112947_bb0195","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/bioinformatics\/btaa987","article-title":"Ultra-fast scalable estimation of single-cell differentiation potency from scRNA-Seq data","volume":"37","author":"Teschendorff","year":"2021","journal-title":"Bioinformatics"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112947_bb0200","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/0008-5472.CAN-21-3565","article-title":"A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer","volume":"82","author":"Rodr\u00edguez","year":"2022","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112947_bb0205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1535-7163.233.3.3","article-title":"Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha","volume":"3","author":"Welsh","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112947_bb0210","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/mol.114.097477","article-title":"Dual targeting of the androgen receptor and hypoxia-inducible factor 1\u03b1 pathways synergistically inhibits castration-resistant prostate cancer cells","volume":"87","author":"Fernandez","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112947_bb0215","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217209","article-title":"Hypoxia-inducible factor 1A inhibition overcomes castration resistance of prostate tumors","volume":"15","author":"Terzic","year":"2023","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112947_bb0220","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/ijc.22062","article-title":"High incidence of EMMPRIN expression in human tumors","volume":"119","author":"Riethdorf","year":"2006","journal-title":"Int. J. Cancer"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826006078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826006078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:26:53Z","timestamp":1792092413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826006078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":44,"alternative-id":["S0898656826006078"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112947","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the HIF-1\u03b1\u2013BSG metabolic circuit reverses enzalutamide resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112947"}}